USPH U S Physical Therapy (USPH) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-health services · CIK 0000885978
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
103
13F, latest reported quarter
What the filings say about USPH
Insiders, 180 days
+$49.3K net bought
1 buyer
Congress, 1 year
No trades
Last one: purchase, 2025-05-20
U S Physical Therapy insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, U S PHYSICAL THERAPY INC /NV insiders bought a net $49.3K of stock across 100 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jun 12, 2026.
- +27.4% median (+24.8% mean) 90-day return after 3 previous buys.
- The trade is 0.2% of the 3,217 shares held after it.
- No other insider bought within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Minan Peter Francis bought about $416 of USPH on Sep 11, 2026; 103 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jun 9, 2026.
- +27.9% median (+27.9% mean) 90-day return after 2 previous buys.
- The trade is 0.0% of the 3,211 shares held after it.
- No other insider bought within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Minan Peter Francis bought about $58 of USPH on Jun 12, 2026; 103 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 8, 2026.
- The trade is 9.0% of the 3,211 shares held after it.
- No other insider bought within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Minan Peter Francis bought about $17.7K of USPH on Jun 9, 2026; 103 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 16.8% of the 2,923 shares held after it.
- No other insider bought within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Minan Peter Francis bought about $31.1K of USPH on Jun 8, 2026; 103 funds added in the latest 13F quarter.Context
- 19 earlier Form 4 trades (code P or S) here by this insider (19 sales), the last on Mar 9, 2026.
- The trade is 2.2% of the 30,078 shares held after it.
- 1 other insider sold within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: COO REEVE GRAHAM D. sold about $52.2K of USPH on Mar 11, 2026; 1 other insider sold within 30 days and 103 funds added in the latest 13F quarter.100 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$49.3K over 180 days
+$416 over 90 days
more than 75% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
103 funds bought in last quarter
below 60% of Healthcare Services
Revenue
+16.3% year over year
more than 62% of Healthcare Services
Margin
5.1% net margin
more than 70% of Healthcare Services
Buybacks
$19.2M repurchased, FY to 2026-06-30
below 71% of Healthcare Services
Short interest
8.2% of the float short (float per yahoo 2026-10-27) · 6.6 days to cover · settled 2026-10-15
more than 81% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch USPH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-2.5%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns USPH: institutional holders (13F)
13F holdings, latest reported quarter
2,264,202 sh
$155.5M
861,574 sh
$59.2M
$58.1M
841,544 sh
$57.8M
707,186 sh
$48.6M
Congress trades in USPH
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2025-05-20 · disclosed 17 days later
$1,001 - $15,000
Sold 2025-04-17 · disclosed 27 days later
$1,001 - $15,000
Bought 2025-01-29 · disclosed 13 days later
$1,001 - $15,000
Bought 2024-10-17 · disclosed 20 days later
$1,001 - $15,000
Sold 2024-09-16 · disclosed 17 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
USPH planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
USPH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
SouthernSun Small Cap Fund
$12.2M position · as of 2026-06-30
4.7%
SouthernSun U.S. Equity Fund
$2.3M position · as of 2026-06-30
4.6%
Virtus KAR Small-Cap Growth Fund
$27.0M position · as of 2026-06-30
4.4%
Virtus KAR Small-Cap Growth Series
$2.0M position · as of 2026-06-30
4.3%
Bahl & Gaynor Small/Mid Cap Income Growth ETF
$39.9M position · as of 2026-06-30
2.7%
Virtus KAR Health Sciences Fund
$2.1M position · as of 2026-06-30
2.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
U.S. Physical Therapy, Inc. Pac
Cycle 2026 · $14K spent
$19.7K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Christopher J. Reading
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$3.4M
$3.8M
$1.7M
-19%
+34%
2022
$2.4M
$1.9M
$1.1M
-29%
+30%
2021
$4.1M
$3.3M
$1.5M
-16%
+35%
2020
$3.0M
$2.4M
$1.1M
+5%
+11%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $49.3K bought by insiders over 180 days, 103 funds added last quarter. Each figure is a federal filing, dated the day it went public.
USPH financials
Revenue growth
+16.3%
XBRL, annual
Net margin
5.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$812.2M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM USPH
| FY Dec 2025 | $781.0M |
| FY Dec 2024 | $671.3M |
| FY Dec 2023 | $604.8M |
| FY Dec 2022 | $553.1M |
| FY Dec 2021 | $495.0M |
| Jun 2026 | $214.1M |
| Mar 2026 | $198.3M |
| Dec 2025 | $202.7M |
| Sep 2025 | $197.1M |
| Jun 2025 | $197.3M |
| Mar 2025 | $183.8M |
| Dec 2024 | $180.4M |
| Sep 2024 | $168.0M |
At each fiscal year end
Single quarter
Net margin, TTM
+4.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM USPH
| FY Dec 2025 | +5.1% |
| FY Dec 2024 | +4.7% |
| FY Dec 2023 | +4.7% |
| FY Dec 2022 | +5.8% |
| FY Dec 2021 | +8.2% |
| Jun 2026 | +4.6% |
| Mar 2026 | +2.5% |
| Dec 2025 | +2.0% |
| Sep 2025 | +6.7% |
| Jun 2025 | +6.3% |
| Mar 2025 | +5.4% |
| Dec 2024 | +5.1% |
| Sep 2024 | +3.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$64.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM USPH
| FY Dec 2025 | $61.0M |
| FY Dec 2024 | $65.8M |
| FY Dec 2023 | $72.7M |
| FY Dec 2022 | $50.3M |
| FY Dec 2021 | $68.2M |
| Jun 2026 | $29.0M |
| Mar 2026 | -$1.6M |
| Dec 2025 | $21.0M |
| Sep 2025 | $15.6M |
| Jun 2025 | $31.6M |
| Mar 2025 | -$7.3M |
| Dec 2024 | $16.9M |
| Sep 2024 | $19.6M |
At each fiscal year end
Single quarter
Debt to equity
0.49x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity USPH
| FY Dec 2025 | 0.34x |
| FY Dec 2024 | 0.31x |
| FY Dec 2023 | 0.31x |
| FY Dec 2022 | 0.58x |
| FY Dec 2021 | 0.40x |
| Jun 2026 | 0.49x |
| Mar 2026 | 0.44x |
| Dec 2025 | 0.34x |
| Sep 2025 | 0.32x |
| Jun 2025 | 0.32x |
| Mar 2025 | 0.33x |
| Dec 2024 | 0.31x |
| Sep 2024 | 0.30x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.38x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt USPH
| FY Dec 2025 | 0.46x |
| FY Dec 2024 | 0.49x |
| FY Dec 2023 | 0.56x |
| FY Dec 2022 | 0.32x |
| FY Dec 2021 | 0.65x |
| Jun 2026 | 0.38x |
| Mar 2026 | 0.41x |
| Dec 2025 | 0.46x |
| Sep 2025 | 0.43x |
| Jun 2025 | 0.45x |
| Mar 2025 | 0.40x |
| Dec 2024 | 0.49x |
| Sep 2024 | 0.58x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+6.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity USPH
| FY Dec 2025 | +8.2% |
| FY Dec 2024 | +6.5% |
| FY Dec 2023 | +7.1% |
| FY Dec 2022 | +10.5% |
| FY Dec 2021 | +14.3% |
| Jun 2026 | +6.8% |
| Mar 2026 | +7.2% |
| Dec 2025 | +8.2% |
| Sep 2025 | +9.1% |
| Jun 2025 | +7.7% |
| Mar 2025 | +6.8% |
| Dec 2024 | +6.5% |
| Sep 2024 | +4.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+2.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets USPH
| FY Dec 2025 | +3.3% |
| FY Dec 2024 | +2.9% |
| FY Dec 2023 | +3.0% |
| FY Dec 2022 | +4.0% |
| FY Dec 2021 | +6.1% |
| Jun 2026 | +2.7% |
| Mar 2026 | +2.9% |
| Dec 2025 | +3.3% |
| Sep 2025 | +4.0% |
| Jun 2025 | +3.5% |
| Mar 2025 | +3.0% |
| Dec 2024 | +2.9% |
| Sep 2024 | +2.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+8.5%
operating income after a 26.1% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital USPH
| FY Dec 2025 | +10.7% |
| FY Dec 2024 | +8.9% |
| FY Dec 2023 | +8.5% |
| FY Dec 2022 | +9.7% |
| FY Dec 2021 | +15.0% |
| Jun 2026 | +8.5% |
| Mar 2026 | +9.0% |
| Dec 2025 | +10.7% |
| Sep 2025 | +11.7% |
| Jun 2025 | +10.1% |
| Mar 2025 | +9.0% |
| Dec 2024 | +8.9% |
| Sep 2024 | +6.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+7.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed USPH
| FY Dec 2025 | +8.2% |
| FY Dec 2024 | +6.5% |
| FY Dec 2023 | +6.1% |
| FY Dec 2022 | +7.9% |
| FY Dec 2021 | +12.1% |
| Jun 2026 | +7.0% |
| Mar 2026 | +7.3% |
| Dec 2025 | +8.2% |
| Sep 2025 | +9.0% |
| Jun 2025 | +7.8% |
| Mar 2025 | +6.9% |
| Dec 2024 | +6.5% |
| Sep 2024 | +4.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
485.22x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing USPH
| FY Dec 2025 | 54.61x |
| FY Dec 2024 | 48.21x |
| FY Dec 2023 | 72.20x |
| FY Dec 2022 | 36.17x |
| FY Dec 2021 | 39.65x |
| Jun 2026 | 381.56x |
| Mar 2026 | 146.98x |
| Dec 2025 | 54.61x |
| Sep 2025 | 35.69x |
| Jun 2025 | 34.15x |
| Mar 2025 | 33.19x |
| Dec 2024 | 48.21x |
| Sep 2024 | 96.17x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.5B
market value at close 2026-10-27 on 2026-08-07 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value USPH
| FY Dec 2025 | $1.3B |
| FY Dec 2024 | $1.5B |
| FY Dec 2023 | $1.4B |
| FY Dec 2022 | $1.2B |
| FY Dec 2021 | $1.3B |
| Jun 2026 | $1.2B |
| Mar 2026 | $1.3B |
| Dec 2025 | $1.3B |
| Sep 2025 | $1.4B |
| Jun 2025 | $1.3B |
| Mar 2025 | $1.2B |
| Dec 2024 | $1.5B |
| Sep 2024 | $1.3B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.9%
TTM free cash flow over market value at close 2026-10-27
FCF yield USPH
| FY Dec 2025 | +5.1% |
| FY Dec 2024 | +4.9% |
| FY Dec 2023 | +5.2% |
| FY Dec 2022 | +4.8% |
| FY Dec 2021 | +5.5% |
| Jun 2026 | +6.1% |
| Mar 2026 | +5.9% |
| Dec 2025 | +5.1% |
| Sep 2025 | +4.4% |
| Jun 2025 | +5.1% |
| Mar 2025 | +5.1% |
| Dec 2024 | +4.9% |
| Sep 2024 | +5.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -92%, PEG needs growth
PEG, trailing USPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | 1.13x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.21x |
| Jun 2025 | 0.26x |
| Mar 2025 | 0.38x |
| Dec 2024 | 1.13x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $781.0M | $671.3M | $604.8M | $553.1M |
| Gross profit | $149.7M | $123.9M | $121.5M | $112.0M |
| Operating income | $86.7M | $63.0M | $50.5M | $56.8M |
| Net income | $39.6M | $31.4M | $28.2M | $32.2M |
| EPS (diluted) | 1.42 | 1.84 | 1.28 | 2.25 |
| Operating cash flow | $75.1M | $74.9M | $82.0M | $58.5M |
| Cash | $35.6M | $41.4M | $152.8M | $31.6M |
| Long-term debt | $152.6M | $142.5M | $139.0M | $175.8M |
| Buybacks | $5.6M | $0 | $0 | n/a |
| Dividends paid | $27.4M | $26.5M | $24.1M | $21.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
USPH Stock Sonar score 6/7 axes
Find similar shapesCompareUSPH ranks highest on insider conviction (68th percentile) and growth (62nd), and lowest on institutional and government (40th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
USPH filings, in plain words
Are U S Physical Therapy insiders buying or selling USPH?
In the 180 days to 2026-10-28, U S Physical Therapy insiders were net buyers, a net $49.3K across purchases and sales reported on Form 4, by 1 buyer.
Have members of Congress traded USPH?
Yes, but not in the year to 2026-10-28; the latest on record is a purchase by Gilbert Cisneros dated 2025-05-20.
Read the full summary
In the 180 days to 2026-10-28, U S Physical Therapy insiders were net buyers of USPH, a net $49.3K across purchases and sales reported on Form 4 by 1 buyer. Members of Congress have disclosed trades in USPH, none in the last year; the latest on record is a purchase by Gilbert Cisneros dated 2025-05-20. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
